Trials / Completed
CompletedNCT00044018
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
An Open-Label Study to Evaluate the Efficacy and Safety of Two CDC-501 Dose Regimens When Used Alone or in Combination With Dexamethasone for the Treatment Relapsed or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CDC-501 |
Timeline
- Start date
- 2002-04-01
- Primary completion
- 2004-12-01
- Completion
- 2007-02-15
- First posted
- 2002-08-20
- Last updated
- 2019-11-12
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00044018. Inclusion in this directory is not an endorsement.